Hostname: page-component-7c8c6479df-fqc5m Total loading time: 0 Render date: 2024-03-29T14:39:08.898Z Has data issue: false hasContentIssue false

O-58 - Suicide and Suicide Attempts During use of Antidepressants: High Risk at Young Age?

Published online by Cambridge University Press:  15 April 2020

F. Termorshuizen
Affiliation:
Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde, University Medical Center, (UMC), Utrecht, The Netherlands
H.M. Smeets
Affiliation:
Julius Centrum voor Gezondheidswetenschappen en Eerstelijns Geneeskunde, University Medical Center, (UMC), Utrecht, The Netherlands
I.M. Engelhard
Affiliation:
Altrecht Institute for Mental Health Care, (UMC), Utrecht, The Netherlands Department of Clinical and Health Psychology, Faculty of Social and Behavioural Sciences, Utrecht University, (UMC), Utrecht, The Netherlands
M.P.M. Boks
Affiliation:
Rudolf Magnus Institute of Neuroscience, Department of Psychiatry, (UMC), Utrecht, The Netherlands

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Since 2003, the Food and Drug Agency (FDA) issued a number of advisory warnings regarding the association between use of antidepressants (ADs) and suicidal behavior, especially among young people. These warnings have led to a more restrictive use of ADs, also among adults.

Objectives

We investigated the rates of (fatal) suicide attempts associated with different classes of ADs at different ages.

Aims

To contribute to finding a favorable balance between safety and the challenge to offer efficacious treatment.

Methods

By linking the Psychiatric Case Register Middle-Netherlands, which contains patients of psychiatric services in the Utrecht region, Agis Health Database, which contains registered insurance claims, and the death register of Statistics Netherlands, rates of (fatal) suicide attempts were estimated.

Results

For 7,725 patients with a depressive disorder (mean age 43.2 years) and with at least one AD delivery, 35,224 episodes of use, 23,840 episodes of no use, 32 suicide events, and 357 suicide attempts were established. No significant differences were found in suicide and suicide attempt rates between the different classes of ADs. Compared to episodes of no use, episodes of use of ADs were significantly associated with higher frequency of suicide attempts but suicide rates were similar. A trend towards an unfavorable effect of ADs on suicide risk at younger age was found (P = 0.0718).

Conclusion

Our results support the FDA advisories in which ADs are treated alike. Use of ADs is indicative of a high risk of suicide, which reiterates the need for close monitoring of patients, especially at young age.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2012
Submit a response

Comments

No Comments have been published for this article.